Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
59.36
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc
Total Assets
Ultragenyx Pharmaceutical Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
|
Total Assets
$1.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
12%
|
CAGR 10-Years
22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$143.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$54.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$22.2B
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$37.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
|
Ultragenyx Pharmaceutical Inc
Glance View
Ultragenyx Pharmaceutical Inc. emerges from the bustling biotech landscape as a company uniquely focused on addressing the unmet needs of rare and ultra-rare genetic diseases. Founded in 2010 by Dr. Emil Kakkis, who has been instrumental in the development of treatments for genetic conditions, Ultragenyx operates with a singular vision: to transform lives through the development and commercialization of novel therapies. The company works diligently at the intersection of biotechnology and medicine, where it utilizes advanced platforms, including gene therapy and biologics, to innovate treatments that specifically target the root causes of these rare diseases. By focusing on conditions with limited treatment options, Ultragenyx not only taps into niche markets but also helps forge new pathways in medical research. Financially, Ultragenyx capitalizes on its comprehensive portfolio of products and promising pipeline of candidates in various stages of development. The company's revenue model is primarily driven by the successful commercialization of its approved therapies, which provide life-changing benefits to patients with rare diseases. This revenue stream is augmented by strategic partnerships and collaborations, which help to mitigate costs and share risks associated with the high stakes of drug development. R&D investments are substantial, reflecting the company's commitment to innovation and long-term growth. In a sector characterized by high research costs and regulatory hurdles, Ultragenyx's targeted approach to niche diseases positions it as a potentially resilient player, with its revenues bolstered by a commitment to addressing critical patient needs.
See Also
What is Ultragenyx Pharmaceutical Inc's Total Assets?
Total Assets
1.5B
USD
Based on the financial report for Sep 30, 2024, Ultragenyx Pharmaceutical Inc's Total Assets amounts to 1.5B USD.
What is Ultragenyx Pharmaceutical Inc's Total Assets growth rate?
Total Assets CAGR 10Y
22%
Over the last year, the Total Assets growth was 24%. The average annual Total Assets growth rates for Ultragenyx Pharmaceutical Inc have been 1% over the past three years , 12% over the past five years , and 22% over the past ten years .
You don't have any saved screeners yet
